Replies to post #383206 on Amarin Corp Plc (AMRN)

[Meowza]

Again, people love fish oil pills. But hate fish oil.

The risk of "statin enhancer" is that there is a significant subset of CVR patients who can't tolerate statins. This was one of the cooler parts of V's R-It indication. Without that, generic IPE for CVR sans statins would be definitively off label, to the extent IP matters for anything (lol).

[ORBAPU]

I agree that Amarin are Olympic gold medalists in buffoonery; however, I doubt they could market Vascepa as a statin enhancer without an explicit trial.

On the other hand, allowing themselves to be overtaken by the fish oil narrative was easily the largest, boldest print “kick me” post-it they ever slapped on their own back.

By the way, I can’t take statins and after 4 years of Vascepa, my LDL and trigs are under 100.